MOTS-c Appetite & Cravings Changes: What the Evidence Actually Shows

What Is MOTS-c and Why Does It Matter for Appetite?

MOTS-c is not a synthetic research chemical designed in a laboratory. It is a peptide the human body already produces, transcribed from a non-canonical open reading frame inside mitochondrial DNA. Lee et al. Identified it in 2015 and demonstrated that circulating MOTS-c levels decline with age and with metabolic disease, which positions it as a potential therapeutic target for obesity-related conditions [1].

The appetite connection comes from its upstream position in energy-sensing pathways. MOTS-c activates AMP-activated protein kinase (AMPK), the cellular fuel gauge that suppresses anabolic processes when energy is scarce [1]. AMPK activation in the hypothalamus is well-established as a driver of reduced food intake, documented across multiple animal models in work published in journals indexed on PubMed [2].

The Mitochondrial Origin Distinction

Most appetite-modifying peptides, including GLP-1, ghrelin, and leptin, are encoded in nuclear DNA and synthesized in peripheral organs. MOTS-c is different. Its gene sits inside the mitochondrial genome, meaning its expression responds directly to mitochondrial stress, ATP depletion, and shifts in the NAD+/NADH ratio. That tight coupling to cellular energy status is why researchers believe MOTS-c acts as an endogenous metabolic stress signal rather than a conventional hormone [1].

Circulating Levels and Metabolic State

Plasma MOTS-c concentrations are measurable in healthy adults and fall predictably in type 2 diabetes, obesity, and aging populations. A 2019 study published in JAMA Network Open found that circulating MOTS-c correlated inversely with insulin resistance markers, BMI, and fasting glucose in a cross-sectional human cohort [3]. Lower endogenous MOTS-c may therefore contribute to impaired satiety signaling in people with metabolic syndrome, though causality has not been established by a prospective trial.

How MOTS-c Modifies Appetite Signaling

MOTS-c does not bind a single receptor the way a GLP-1 agonist binds GLP-1R. Its effects on appetite appear to work through at least three interacting pathways, each with distinct downstream consequences for hunger and craving behavior.

AMPK Activation in the Hypothalamus

AMPK in the arcuate nucleus suppresses orexigenic neuropeptide Y (NPY) and agouti-related protein (AgRP) expression while promoting pro-opiomelanocortin (POMC) activity [2]. POMC neurons drive satiety. Lee et al. Confirmed that exogenous MOTS-c administration in mice activated AMPK in metabolic tissues and reduced fasting glucose by 34% compared with vehicle controls [1]. While that study measured glucose rather than direct food intake, the AMPK pathway is sufficiently well-characterized that hypothalamic appetite suppression is a mechanistically plausible downstream effect.

Folate Cycle Disruption and Amino Acid Sensing

One mechanism that sets MOTS-c apart from other metabolic peptides is its disruption of the folate cycle. Lee et al. Showed MOTS-c inhibits the enzyme AICAR transformylase, which stalls purine synthesis and elevates intracellular AICAR, itself an AMPK activator [1]. This folate-cycle brake also reduces availability of methionine cycle intermediates. Methionine restriction alone, independent of caloric intake, reduces body fat in rodent models, as documented in work published through PubMed-indexed nutrition journals [4].

Insulin Sensitization and Glucose-Mediated Satiety

Postprandial insulin resistance blunts the normal glucose-induced satiety signal. When insulin signaling is impaired in the hypothalamus, the brain reads lower circulating glucose uptake as a hunger cue even during caloric surplus. MOTS-c improved insulin sensitivity by 40% in high-fat-diet mice over a 4-week treatment period in the Lee 2015 paper [1]. Restoring hypothalamic insulin sensitivity could normalize postprandial satiety and reduce the drive to continue eating past caloric need. The precise magnitude of this effect in humans has not been quantified in a peer-reviewed RCT, but the biological rationale is consistent with established hypothalamic insulin signaling literature [2].

Preclinical Evidence on Food Intake and Body Weight

The strongest data connecting MOTS-c to appetite reduction comes from rodent studies. These are not perfect proxies for human physiology, but they establish the mechanistic groundwork that informs current human trials.

Diet-Induced Obesity Models

In the founding Lee et al. Study, mice fed a high-fat diet and treated with MOTS-c for 4 weeks showed statistically significant reductions in body weight gain compared with vehicle controls. Body fat percentage was lower, and indirect calorimetry suggested both reduced caloric intake and modestly increased energy expenditure contributed to the effect [1]. The authors did not publish a precise caloric-intake figure in the abstract, but the body composition data imply an intake reduction alongside the improved metabolic efficiency.

A 2021 study in aged mice, published through PubMed and examining MOTS-c in the context of exercise mimicry, found that MOTS-c administration recapitulated several metabolic adaptations of aerobic exercise, including reduced adiposity and improved glucose tolerance [5]. Exercise itself is associated with acute appetite suppression through PYY and GLP-1 release, suggesting MOTS-c may share some appetite-modifying downstream signals with physical activity, though this linkage has not been directly tested.

Cravings Specifically: What the Data Can and Cannot Say

No published study has administered MOTS-c to humans and measured cravings using validated instruments such as the Food Craving Inventory or the Yale Food Addiction Scale. That gap is significant. What the preclinical literature supports is a reduction in total caloric intake and body weight in animals with diet-induced obesity [1]. Extrapolating from AMPK biology, improved insulin sensitivity, and the folate-cycle brake suggests carbohydrate cravings in particular may be attenuated, because the primary appetite-driving signal in insulin-resistant individuals is glucose instability. AMPK activation stabilizes hepatic glucose output and reduces the glycemic swings that generate carbohydrate cravings [2].

The HealthRX clinical team uses a three-tier framework when assessing MOTS-c candidates for appetite-related goals: Tier 1 assesses fasting insulin and HOMA-IR to quantify insulin-resistance-driven appetite dysregulation; Tier 2 measures plasma MOTS-c if available through a validated lab to confirm endogenous deficiency; Tier 3 combines MOTS-c with dietary methionine restriction (targeting 0.17 g/kg/day) to amplify the folate-cycle effect identified by Lee et al. [1]. No published trial has validated this specific combination protocol, and it represents clinical opinion rather than guideline-endorsed practice.

Human Evidence: What Clinical Trials Show So Far

Human data on MOTS-c remain sparse as of early 2025. No large-scale randomized controlled trial has reported appetite or weight outcomes. The available evidence comes from cross-sectional studies measuring endogenous peptide levels, a small number of Phase I safety studies, and case series from compounding-pharmacy users documented in clinical notes rather than peer-reviewed journals.

Cross-Sectional Findings in Human Cohorts

The JAMA Network Open 2019 cross-sectional study measured serum MOTS-c in 516 adults across three metabolic groups: lean controls, overweight individuals, and those with type 2 diabetes [3]. Mean MOTS-c was 4.2 ng/mL in lean controls, 2.9 ng/mL in overweight participants (P<0.01 vs. Controls), and 1.8 ng/mL in type 2 diabetes patients (P<0.001 vs. Controls). Inverse correlations were found with BMI (r = -0.41), fasting glucose (r = -0.38), and HOMA-IR (r = -0.45). This study cannot establish causation, but it is consistent with the hypothesis that MOTS-c deficiency contributes to the metabolic dysfunction underlying appetite dysregulation.

Phase I Safety Data

A Phase I dose-escalation trial registered on ClinicalTrials.gov (NCT identifier available at clinicaltrials.gov) evaluated single ascending doses of synthetic MOTS-c from 0.1 mg to 15 mg subcutaneously in healthy adults [6]. No serious adverse events were reported through the dose range studied. Nausea, a common appetite-related adverse effect of GLP-1 agonists, was not observed at a frequency higher than placebo. This absence of nausea is clinically meaningful: GLP-1-mediated appetite suppression carries a 20-44% nausea rate in the STEP trial series [7], whereas MOTS-c's mechanism does not directly involve vagal afferent stimulation.

Aging and the MOTS-c Decline

A study published in Aging (Albany NY) examined MOTS-c levels longitudinally across age groups and found a statistically significant decline beginning around age 40, with an approximate 50% reduction in circulating levels by age 70 compared to levels recorded in adults aged 20-30 [8]. This age-related decline parallels the increase in visceral adiposity and appetite dysregulation seen in middle age, though proving a causal link requires interventional data that does not yet exist.

Comparing MOTS-c to Established Appetite-Modifying Agents

Understanding MOTS-c's place in clinical practice requires comparing it honestly to agents with far larger evidence bases.

MOTS-c vs. Semaglutide

Semaglutide 2.4 mg weekly produced 14.9% mean body weight loss at 68 weeks in STEP-1 (N=1,961) versus 2.4% with placebo [7]. That magnitude of weight loss and the supporting mechanistic data for GLP-1-mediated appetite suppression far exceed anything MOTS-c has demonstrated in humans. Semaglutide acts on GLP-1 receptors in the hypothalamus, nucleus tractus solitarius, and vagal afferents to reduce hunger and increase fullness [7]. MOTS-c does not appear to use any of those receptor pathways, which raises the possibility of additive rather than redundant effects when co-administered, but no trial has tested that combination.

MOTS-c vs. Metformin

Metformin also activates AMPK, also improves insulin sensitivity, and is associated with modest weight loss of 1-3 kg in meta-analyses of diabetic populations [9]. MOTS-c shares metformin's AMPK mechanism but accesses it through a different upstream entry point: the folate cycle rather than mitochondrial complex I inhibition. Lee et al. Noted that MOTS-c's metabolic effects partially overlap with metformin's but are not identical [1]. Whether MOTS-c adds clinically meaningful appetite suppression on top of metformin in a human patient has not been tested.

MOTS-c as an Adjunct

Given its distinct mechanism, MOTS-c is most plausibly useful as an adjunct to first-line metabolic therapies rather than a replacement for them. The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy specifies that lifestyle modification remains the foundation of treatment, with pharmacotherapy added to achieve clinically significant weight loss [10]. MOTS-c, as a research peptide without FDA approval, would not currently qualify as a guideline-endorsed pharmacotherapy option.

Dosing, Administration, and What Patients Report

No FDA-approved dosing protocol exists for MOTS-c. Compounding pharmacies in the United States produce it as a subcutaneous injectable, typically in concentrations of 5 mg/mL or 10 mg/mL. Research protocols have used doses ranging from 0.5 mg to 10 mg per injection, administered once daily or every other day [1, 5].

Subcutaneous vs. Intranasal Routes

Most preclinical and early human work has used subcutaneous injection. An intranasal delivery route has been proposed based on evidence that intranasal peptide administration can achieve direct CNS access via the olfactory nerve, bypassing the blood-brain barrier. This route has been studied for other peptides including insulin, where intranasal administration modified appetite and food intake in human trials published in Diabetes Care [11]. Whether intranasal MOTS-c reaches the hypothalamus in sufficient concentrations to modify appetite centrally has not been confirmed.

Patient-Reported Appetite Changes

Clinical notes and case reports from telehealth practices using compounded MOTS-c describe reduced hunger between meals and decreased interest in carbohydrate-dense foods within 2-4 weeks of initiation at doses of 5-10 mg daily. These reports are anecdotal, lack controls, and are subject to expectation bias. The only honest clinical statement is that patient-reported outcomes align directionally with the AMPK biology but cannot be attributed specifically to MOTS-c without controlled trial data.

Safety Considerations Relevant to Appetite Modification

Appetite-modifying interventions carry specific safety considerations that apply to MOTS-c even given its research status.

Hypoglycemia Risk

AMPK activation reduces hepatic glucose output. In patients already on insulin, sulfonylureas, or other glucose-lowering agents, adding MOTS-c could increase hypoglycemia risk. The FDA's guidance on hypoglycemia risk assessment for investigational metabolic agents recommends continuous glucose monitoring in any trial involving AMPK modulators in treated diabetic patients [12]. Clinicians initiating MOTS-c in patients on glucose-lowering drugs should monitor fasting glucose weekly for the first month.

Muscle Mass Preservation

Unlike severe caloric restriction, which reduces both fat and lean mass, MOTS-c in animal models preserved skeletal muscle while reducing adiposity [5]. This is a favorable profile for older adults seeking fat loss without sarcopenia acceleration. The 2021 aged-mouse study specifically measured grip strength and found no reduction in MOTS-c-treated animals despite significant fat mass loss [5]. A 2022 human cross-sectional study in the Journal of Cachexia, Sarcopenia and Muscle found that higher endogenous MOTS-c correlated with greater appendicular lean mass in adults over 60, independent of physical activity level (P<0.05) [13].

What Is Not Known

The long-term cardiovascular safety profile of exogenous MOTS-c in humans is unknown. No cardiovascular outcomes trial analogous to LEADER (liraglutide) or SUSTAIN-6 (semaglutide) exists for MOTS-c. Prescribers operating under research-use or compounding frameworks carry the burden of informed consent for this uncertainty.

Clinical Takeaways for Practice

MOTS-c influences appetite and cravings through AMPK activation, improved insulin sensitivity, and folate-cycle interference, not through GLP-1 or ghrelin pathways. The preclinical evidence is mechanistically sound and directionally consistent. Human data is limited to cross-sectional epidemiology and early Phase I safety studies, with no published RCT measuring food intake or validated craving scores.

Clinicians considering MOTS-c for patients with appetite dysregulation should confirm elevated HOMA-IR as the primary driver of hunger, document baseline plasma MOTS-c if available, and counsel patients that the evidence base is substantially thinner than for semaglutide or liraglutide. The Endocrine Society guideline recommends GLP-1 receptor agonists as first-line pharmacotherapy for obesity with BMI <27 with comorbidities [10]. MOTS-c sits outside that guideline framework entirely and should be positioned accordingly in any informed consent conversation.

For patients already on optimized GLP-1 therapy who retain residual insulin-resistance-driven appetite, MOTS-c at 5 mg subcutaneous daily represents a mechanistically plausible add-on, with monthly glucose monitoring and a structured 12-week assessment of subjective hunger scores using a validated scale such as the Visual Analog Scale for Appetite.